Clinical Trial

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

Study acronym: BAH244
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated December 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD33 or CD123 or both sequentially in the treatment of Acute Myelocytic Leukemia.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-14; most recent amendment 2024-11-10.
Status change: Not Yet Recruiting → Recruiting 2024-07-29
Trial Details
NCT Number NCT06420063
Lead Sponsor Essen Biotech
Conditions AML, Acute Myeloid Leukemia, AML, Adult Recurrent, AML, Adult
Enrollment 85 participants
Start Date 2024-07-10
Primary Completion 2025-12-10 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2024-11-12